X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Truseltiq (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven gastric cancer or gastroesophageal junction adenocarcinoma and to target achondroplasia at its source.
Lead Product(s): Infigratinib
Therapeutic Area: Oncology Product Name: BGJ398
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: LianBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
BridgeBio will retain all rights to infigratinib in skeletal dysplasia, including achondroplasia. Subject to U.S. FDA approval, QED and Helsinn will co-commercialize infigratinib in oncology indications in the U.S. and will share profits and losses on a 50:50 basis.
Lead Product(s): Infigratinib
Therapeutic Area: Oncology Product Name: BGJ398
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: BridgeBio Pharma
Deal Size: $2,000.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 31, 2021
Details:
The U.S. FDA has accepted New Drug Application (NDA) for infigratinib, an oral FGFR1-3 selective inhibitor, for individuals with cholangiocarcinoma, or cancer of the bile ducts. Application accepted under Priority Review designation.
Lead Product(s): Infigratinib
Therapeutic Area: Oncology Product Name: BGJ398
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: BridgeBio Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Data will be presented reports consistent treatment response in both first-line and later-line treatment settings after Infigratinib (BGJ398) treatment in advanced/unresectable or metastatic urothelial carcinoma.
Lead Product(s): Infigratinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
The PROOF 302 trial is studying infigratinib for adjuvant treatment of invasive urothelial carcinoma. Second, investigator-initiated trial, is studying infigratinib for the treatment of solid tumors.
Lead Product(s): Infigratinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
